Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - OraPharma, Inc. (NasdaqNM:OPHM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 16Price hit new 52-week low ($3.50)
Location
732 Louis Drive
Warminster, PA 18974
Phone: (215) 956-2200
Fax: (215) 443-9531
Email: skuharcik@orapharma.com
Employees (last reported count): 82
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 40%
·Institutional: 46% (77% of float)
(45 institutions)
·Net Inst. Buying: 2.12M shares (+25.46%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
OraPharma, Inc. is a specialty pharmaceutical company that is engaged in discovering, developing and commercializing pharmaceutical products for oral healthcare. In February 2001, the Company received approval from the United States Food and Drug Administration to market the Company's first product, Arestin. The Company's other product candidates, which are in earlier stages of development, include a compound for the treatment of oral mucositis, an agent for bone and tissue regeneration, a second treatment approach for periodontitis as a follow-on to Arestin and a dental trauma treatment using Arestin. OraPharma is directing its research and development programs at further establishing a presence in oral health care pharmaceuticals and expanding the use of its core technology.
More from Market Guide: Expanded Business Description

Financial Summary
OraPharma, Inc. is a specialty pharmaceutical company that is engaged in discovering, developing and commercializing pharmaceutical products for oral healthcare. Its first product is for the treatment of adult periodontitis. For the six months ended 6/30/01, revenue totaled $2 million, up from $0. Net loss totaled $13.5 million, up from $4.3 million. Results reflect initial revenues from the sale of Arestin, offset by increased sales and marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Michael Kishbauch, 51
Pres, CEO, Director
$320K--  
James Ratigan, 52
CFO, Exec. VP, Sec.
236K$508K
J. Ronald Lawter, Ph.D., 58
Exec. VP, CTO, Chief Scientific Officer
229K43K
Joseph Zack, 49
VP of Sales and Marketing
214K103K
Mark Carbeau, 40
VP, Corp. Devel.
272K281K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:OPHMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 16-Aug-2001
$3.50 
Recent Price$5.24 
52-Week High
on 2-Oct-2000
$14.938
Daily Volume (3-month avg)24.9K
Daily Volume (10-day avg)9,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-50.7%
52-Week Change
relative to S&P500
-33.8%
Share-Related Items
Market Capitalization$70.8M
Shares Outstanding13.5M
Float8.10M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.68 
Earnings (ttm)-$1.61 
Earnings (mrq)-$0.50 
Sales (ttm)$0.15 
Cash (mrq)$4.17 
Valuation Ratios
Price/Book (mrq)1.12 
Price/EarningsN/A 
Price/Sales (ttm)34.67 
Income Statements
Sales (ttm)$2.01M
EBITDA (ttm)-$24.8M
Income available to common (ttm)-$21.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-27.20%
Return on Equity (ttm)-28.54%
Financial Strength
Current Ratio (mrq)11.04 
Debt/Equity (mrq)0 
Total Cash (mrq)$56.4M
Short Interest
As of 8-Aug-2001
Shares Short24.0K
Percent of Float0.3%
Shares Short
(Prior Month)
19.0K
Short Ratio1.14 
Daily Volume21.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.